SCHEMBL7030706

SCHEMBL7030706

Cc1ccc(C)c(C(=O)c2ccc(Nc3cnccc3C)cc2Cl)c1

nearest known ligand 0.57

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
MAPK13 O15264 10/20 0.57
MAPK12 P53778 10/20 0.57
MAPK11 Q15759 10/20 0.57
MAPK14 Q16539 10/20 0.57
DHODH Q02127 3/20 0.49
PTGS1 P23219 2/20 0.45
PTGS2 P35354 2/20 0.45
KDM4C Q9H3R0 1/20 0.43
MEN1 O00255 1/20 0.40
NPC1 O15118 1/20 0.40
KMT2A Q03164 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7034038 0.87 MAPK14 (0.76) MAPK13MAPK12MAPK11MAPK14DHODH
SCHEMBL7030643 0.86 DHODH (0.44) MAPK13MAPK12MAPK11MAPK14DHODH
SCHEMBL7036427 0.85 MAPK13 (0.58) MAPK13MAPK12MAPK11MAPK14PTGS1
SCHEMBL7037065 0.84 DHODH (0.43) MAPK13MAPK12MAPK11MAPK14DHODH
SCHEMBL7033698 0.83 MAPK14 (0.59) MAPK13MAPK12MAPK11MAPK14DHODH
SCHEMBL7030642 0.82 KDM4C (0.44) MAPK13MAPK12MAPK11MAPK14DHODH
SCHEMBL7036535 0.82 MAPK13 (0.55) MAPK13MAPK12MAPK11MAPK14DHODH
SCHEMBL7079244 0.80 MAPK14 (0.75) MAPK13MAPK12MAPK11MAPK14PTGS1
SCHEMBL5174760 0.78 MAPK13 (0.63) MAPK13MAPK12MAPK11MAPK14MEN1
SCHEMBL7030742 0.76 MAPK14 (0.55) MAPK13MAPK12MAPK11MAPK14DHODH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1289958-A2 BENZOPHENONES AS INHIBITORS OF IL-1$g(b) AND TNF-$g(a) Leo Pharma A/S (DK) 2003-03-12 EP claimed
US-6432962-B2 Benzophenones as inhibitors of IL-1β and TNF-α LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) 2002-08-13 US claimed
US-20020016347-A1 Benzophenones as inhibitors of IL-1beta and TNF-alpha LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) 2002-02-07 US claimed
WO-2001090074-A2 BENZOPHENONES AS INHIBITORS OF IL-1β AND TNF-$g(a) LEO PHARMA A/S (DK) 2001-11-29 WO claimed
EP-1289958-A2 BENZOPHENONES AS INHIBITORS OF IL-1$g(b) AND TNF-$g(a) Leo Pharma A/S (DK) 2003-03-12 EP disclosed
US-6432962-B2 Benzophenones as inhibitors of IL-1β and TNF-α LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) 2002-08-13 US disclosed
US-20020016347-A1 Benzophenones as inhibitors of IL-1beta and TNF-alpha LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) 2002-02-07 US disclosed
WO-2001090074-A2 BENZOPHENONES AS INHIBITORS OF IL-1β AND TNF-$g(a) LEO PHARMA A/S (DK) 2001-11-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020016347-A1 Benzophenones as inhibitors of IL-1beta and TNF-alpha IL1B, IL1A, NFKBIA MAPK13 1908/4885MAPK12 1184/4885MAPK11 2116/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.